AlzChem Group Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
AlzChem Group wird ein jährliches Gewinn- und Umsatzwachstum von 19.1% bzw. 11.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 27% betragen.
Wichtige Informationen
19.1%
Wachstumsrate der Gewinne
18.97%
EPS-Wachstumsrate
| Chemicals Gewinnwachstum | 43.6% |
| Wachstumsrate der Einnahmen | 11.2% |
| Zukünftige Eigenkapitalrendite | 27.00% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 07 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 4.0% to close at €156 following the...Analyseartikel • Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 6.3% to close at €77.80 following the...Recent updates
Narrativ-Update • May 24
ACT: Specialty Chemicals Moat And 2026 Expansions Will Support Future Cash Generation
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved higher to €200, with analysts pointing to recent research that highlights confidence in the company’s specialty chemicals focus and its potential for high margin projects and cash generation in the coming years. Analyst Commentary Recent research shows a clear uptick in confidence from bullish analysts, with several price target revisions pointing to stronger conviction around AlzChem Group's specialty chemicals focus and project pipeline.Analyseartikel • May 08
Investors Shouldn't Be Too Comfortable With AlzChem Group's (ETR:ACT) Earnings
Despite announcing strong earnings, AlzChem Group AG's ( ETR:ACT ) stock was sluggish. Our analysis uncovered some...Narrativ-Update • May 01
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.
Narrativ-Update • Apr 17
ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.Narrativ-Update • Apr 03
ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential
The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.
Narrativ-Update • Mar 20
ACT: Specialty Chemicals Platform And 2026 Expansion Plans Will Support Upside
Analysts have lifted the implied fair value estimate for AlzChem Group to about €185 from roughly €177, supported by higher Street price targets in the €195 to €197 range and confidence in the company's specialty chemicals focus and production platform. Analyst Commentary Recent research updates point to a constructive tone from bullish analysts, who see the higher price targets as aligned with confidence in AlzChem Group's business model and execution around specialty chemicals.Narrativ-Update • Mar 06
ACT: Specialty Chemicals Moat And 2026 Projects Will Drive Future Upside
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved from €185 to €195, with analysts highlighting the company's specialty chemicals performance, unique production platform and high margin growth projects as key factors in their updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on AlzChem Group, pointing to recent research updates as support for higher valuation expectations and confidence in the company’s execution.Narrativ-Update • Feb 19
ACT: New Creatine Capacity Plan Will Support Measured Long Term Upside Potential
Analysts are holding their price target for AlzChem Group steady at €165.00. They explain the unchanged view by pointing to updated assumptions that combine a slightly higher discount rate and P/E multiple with adjusted revenue growth and profit margin expectations.Narrativ-Update • Feb 05
ACT: New Creatine Investment Program Will Support Long Term Upside Potential
Analysts have lifted their price target on AlzChem Group from €150.00 to €165.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple in their models. What's in the News AlzChem Group AG has approved an investment program of around €120 million aimed at supporting additional profitable growth and reinforcing its presence in specialty chemicals for sports, food, and health (company announcement).Analyseartikel • Jan 23
Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?
Key Insights AlzChem Group's estimated fair value is €231 based on 2 Stage Free Cash Flow to Equity Current share price...Narrativ-Update • Jan 21
ACT: New Creatine Plant And 2025 Outlook Will Underpin Balanced Prospects
Analysts have modestly trimmed their price target for AlzChem Group to €176.94 from €179.93 as minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations feed into a slightly lower fair value estimate. What's in the News AlzChem Group AG approved an investment program of around €120 million to build a more automated production plant for creatine and its precursors, along with related infrastructure, targeting additional growth in sports, food and health (Key Developments).Narrativ-Update • Jan 07
ACT: New Creatine Capacity Expansion And 2025 Record Outlook Will Support Upside
Analysts now set a higher fair value target for AlzChem Group at €179.93 compared with €167.10 previously. They point to updated assumptions for revenue growth, profit margins and a lower future P/E multiple.Narrativ-Update • Dec 16
ACT: New Creatine Capacity And Partnerships Will Support Balanced Long Term Outlook
Analysts have raised their price target for AlzChem Group from €97.00 to €150.00, citing slightly stronger expectations for long term revenue growth and a higher justified future P E multiple, despite a modestly lower profit margin outlook. What's in the News AlzChem Group has approved an approximately EUR 120 million investment program to build a more automated creatine production plant and related infrastructure, targeting additional annual sales in the early triple-digit million euro range.Narrativ-Update • Dec 02
ACT: Earnings Guidance And New Product Launch Will Drive Record Performance
Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.Analyseartikel • Nov 24
AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 21.1x AlzChem Group AG ( ETR:ACT ) may be sending bearish signals at the...Narrativ-Update • Nov 18
ACT: Strong Revenue Outlook And Product Launches Will Drive Upside Momentum
Analysts have raised their price target for AlzChem Group from €163.10 to €167.10, citing improved revenue growth forecasts. These improved forecasts have offset slight adjustments in the discount rate and profit margin expectations.Narrativ-Update • Nov 02
ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation
Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.Analyseartikel • Oct 13
AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate
Key Insights AlzChem Group's estimated fair value is €236 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...Analyseartikel • Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrativ-Update • Aug 20
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.Analyseartikel • Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
While AlzChem Group AG ( ETR:ACT ) might not have the largest market cap around , it received a lot of attention from a...Narrativ-Update • Aug 06
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.Analyseartikel • Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 4.0% to close at €156 following the...Analyseartikel • Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
AlzChem Group AG ( ETR:ACT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...Analyseartikel • Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analyseartikel • May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)
Key Insights AlzChem Group's estimated fair value is €119 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...Analyseartikel • May 05
What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You
Despite an already strong run, AlzChem Group AG ( ETR:ACT ) shares have been powering on, with a gain of 29% in the...Analyseartikel • May 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG ( ETR:ACT ) will increase its dividend from last year's comparable payment on the 13th of May to...Analyseartikel • May 01
Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it received a lot of attention from a substantial...Analyseartikel • Mar 28
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
The board of AlzChem Group AG ( ETR:ACT ) has announced that it will be paying its dividend of €1.80 on the 13th of...Analyseartikel • Mar 18
With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 6.3% to close at €77.80 following the...Analyseartikel • Mar 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG's ( ETR:ACT ) periodic dividend will be increasing on the 13th of May to €1.80, with investors...Analyseartikel • Feb 19
Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
With a price-to-earnings (or "P/E") ratio of 14.1x AlzChem Group AG ( ETR:ACT ) may be sending bullish signals at the...
Neues Narrativ • Feb 17
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.Analyseartikel • Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
AlzChem Group AG ( ETR:ACT ) just reported healthy earnings but the stock price didn't move much. Investors are...Analyseartikel • Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
AlzChem Group AG ( ETR:ACT ) shareholders would be excited to see that the share price has had a great month, posting a...Analyseartikel • Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it saw a significant share price rise of 46% in the...Analyseartikel • Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AlzChem Group fair value estimate is €43.94 AlzChem Group's...Analyseartikel • May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
AlzChem Group AG's ( ETR:ACT ) recent earnings report didn't offer any surprises, with the shares unchanged over the...Analyseartikel • May 01
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
Key Insights AlzChem Group will host its Annual General Meeting on 7th of May Total pay for CEO Andreas Niedermaier...Analyseartikel • Apr 26
AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
AlzChem Group AG ( ETR:ACT ) has announced that it will be increasing its dividend from last year's comparable payment...Analyseartikel • Apr 11
Is AlzChem Group (ETR:ACT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Mar 29
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
The board of AlzChem Group AG ( ETR:ACT ) has announced that it will be paying its dividend of €1.20 on the 10th of...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 815 | 108 | 94 | 118 | 5 |
| 12/31/2027 | 705 | 87 | -14 | 89 | 6 |
| 12/31/2026 | 606 | 67 | 1 | 145 | 6 |
| 3/31/2026 | 581 | 67 | 4 | 125 | N/A |
| 12/31/2025 | 575 | 63 | 39 | 137 | N/A |
| 9/30/2025 | 576 | 62 | 102 | 146 | N/A |
| 6/30/2025 | 568 | 58 | 69 | 113 | N/A |
| 3/31/2025 | 559 | 56 | 72 | 121 | N/A |
| 12/31/2024 | 563 | 54 | 62 | 105 | N/A |
| 9/30/2024 | 564 | 50 | 82 | 103 | N/A |
| 6/30/2024 | 555 | 46 | 76 | 97 | N/A |
| 3/31/2024 | 546 | 39 | 73 | 96 | N/A |
| 12/31/2023 | 546 | 35 | 52 | 73 | N/A |
| 9/30/2023 | 533 | 30 | 25 | 55 | N/A |
| 6/30/2023 | 554 | 28 | 24 | 53 | N/A |
| 3/31/2023 | 570 | 30 | -15 | 12 | N/A |
| 12/31/2022 | 550 | 30 | -33 | -4 | N/A |
| 9/30/2022 | 534 | 29 | -25 | 4 | N/A |
| 6/30/2022 | 487 | 28 | -28 | 0 | N/A |
| 3/31/2022 | 454 | 27 | 3 | 29 | N/A |
| 12/31/2021 | 429 | 28 | 14 | 43 | N/A |
| 9/30/2021 | 420 | 27 | 11 | 40 | N/A |
| 6/30/2021 | 406 | 26 | 34 | 63 | N/A |
| 3/31/2021 | 397 | 23 | 14 | 48 | N/A |
| 12/31/2020 | 386 | 20 | 20 | 49 | N/A |
| 9/30/2020 | 370 | 16 | 10 | 52 | N/A |
| 6/30/2020 | 389 | 17 | 11 | 53 | N/A |
| 3/31/2020 | 387 | 17 | 20 | 54 | N/A |
| 12/31/2019 | 385 | 18 | N/A | 44 | N/A |
| 9/30/2019 | 389 | 19 | N/A | 42 | N/A |
| 6/30/2019 | 380 | 18 | N/A | 22 | N/A |
| 3/31/2019 | 380 | 20 | N/A | 33 | N/A |
| 12/31/2018 | 383 | 23 | N/A | 35 | N/A |
| 9/30/2018 | 380 | 22 | N/A | 24 | N/A |
| 6/30/2018 | 398 | 32 | N/A | 31 | N/A |
| 3/31/2018 | 364 | 21 | N/A | 23 | N/A |
| 12/31/2017 | 361 | 20 | N/A | 31 | N/A |
| 9/30/2017 | 356 | 22 | N/A | 31 | N/A |
| 12/31/2016 | 333 | 15 | N/A | 33 | N/A |
| 9/30/2016 | 331 | 12 | N/A | 39 | N/A |
| 12/31/2015 | 329 | 15 | N/A | 30 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ACTDas prognostizierte Gewinnwachstum (19.1% pro Jahr) liegt über der Sparquote (1.9%).
Ertrag vs. Markt: ACTDie Erträge des Unternehmens (19.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (17.2% pro Jahr).
Hohe Wachstumserträge: ACTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: ACTDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (6.7% pro Jahr).
Hohe Wachstumseinnahmen: ACTDie Einnahmen des Unternehmens (11.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ACTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (27%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/29 00:06 |
| Aktienkurs zum Tagesende | 2026/05/29 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AlzChem Group AG wird von 8 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Konstantin Wiechert | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Gerhard Orgonas | Berenberg |